Global state: No clinically important improvement ‐ global evaluation ‐ when compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia
STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in global state: No clinically important improvement ‐ global… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
ULTRA LOW DOSE (<2 mg/day) showed no clear difference in leaving the study early: Any reason ‐ when compared with… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Mental state: No clinically important improvement · patients with schizophrenia
STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in mental state: No clinically important improvement ‐ PANSS ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Leaving the study early: insufficient response ‐ When compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia
HIGH DOSE (greater than or equal to 10 mg/day) showed no clear difference in leaving the study early: insufficient response ‐ When compared with… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Global state: No clinically important improvement ‐ global evaluation ‐ when compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia
HIGH DOSE (greater than or equal to 10 mg/day) showed no clear difference in global state: 1. No clinically important improvement ‐ CGI‐I ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Mental state: No clinically important improvement · patients with schizophrenia
HIGH DOSE (greater than or equal to 10 mg/day) leads to higher mental state: 1. No clinically important improvement ‐ PANSS ‐ when… compared with ANY DOSE ‐ short term (high certainty).
1 finding from 1 review
Adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia
HIGH DOSE (greater than or equal to 10 mg/day) probably leads to higher adverse effects: EPS: unspecified ‐ when compared with… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Mental state: No clinically important improvement · patients with schizophrenia
ULTRA LOW DOSE (<2 mg/day) probably leads to higher mental state: 1. No clinically important improvement ‐ as measured… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
LOW DOSE (greater than or equal to 2‐<4 mg/day) probably leads to higher leaving the study early: any reason ‐ when compared with… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Mortality, near term corrected age or discharge · preterm infants
Lower showed no clear difference in mortality, near term corrected age or discharge compared with higher oxygen concentrations titrated to target oxygen saturations… (low certainty).
1 finding from 1 review
Neurodevelopmental disability · preterm infants
Lower showed no clear difference in neurodevelopmental disability compared with higher oxygen concentrations titrated to target oxygen saturations… (low certainty).
1 finding from 1 review
Intubation in the delivery room · preterm infants
Lower showed no clear difference in intubation in the delivery room compared with higher oxygen concentrations titrated to target oxygen saturations… (low certainty).
1 finding from 1 review
Severe (defined as stage 3 or greater) retinopathy of prematurity ‐ not reported · preterm infants
Lower showed no clear difference in severe retinopathy of prematurity (≥ stage 3) compared with higher oxygen concentrations titrated to target oxygen saturations… (low certainty).
1 finding from 1 review
Severe intraventricular haemorrhage · preterm infants
Lower showed no clear difference in severe intraventricular haemorrhage (grade 3 or 4) compared with higher oxygen concentrations titrated to target oxygen saturations… (low certainty).
1 finding from 1 review
Necrotising enterocolitis · preterm infants
Lower showed no clear difference in necrotising enterocolitis compared with higher oxygen concentrations titrated to target oxygen saturations… (low certainty).
1 finding from 1 review
Chronic lung disease · preterm infants
It is very uncertain whether lower changes chronic lung disease (36 weeks' corrected age) compared with higher oxygen concentrations titrated to target oxygen saturations… (very low certainty).
1 finding from 1 review
Rate of weight gain (g/kg/day) · patients with preterm infants
1 finding from 1 review
Proportion of infants having at least one episode of low temperature requiring overhead heater use · patients with preterm infants
Transfer from incubator to cot at lower showed no clear difference in proportion of infants having at least one episode of low temperature… compared with higher body weight (high certainty).
1 finding from 1 review
Proportion of infants having at least one episode of returning to incubator · patients with preterm infants
Transfer from incubator to cot at lower showed no clear difference in proportion of infants having at least one episode of returning to… compared with higher body weight (moderate certainty).
1 finding from 1 review
Duration from transfer to cot to discharge home (days) · patients with preterm infants
1 finding from 1 review